In a recently released analyst research update, AltaCorp Capital Senior Equity Research Analyst David Kideckel reiterated his buy rating on shares of Latin America-focused cannabis company Khiron Life Sciences Corp. (TSXV:KHRV) (OTC:KHRNF) (FRA:A2JMZC) with a price target that suggests some huge upside to come.
Yesterday, Khiron announced that its wholly-owned clinic network, the Latin American Institute of Neurology and the Nervous System, has partnered with leading Colombian insurance company EPS SURA to launch a four-month pilot program that will provide medical services to an initial group of 450 patients.
With revenues of $1.2 billion CAD in 2018, EPS SURA is one of the largest insurance companies in Colombia and forms part of the wider Suramericana S.A. network across Latin America.
David Kideckel’s current KHRN price target of $6.00 CAD per share implies a potential upside of approximately 187.08% based on the last traded price of $2.09 CAD per share on the TSXV.
According to Cantech Letter, “Kideckel thinks that KHRN is currently undervalued.”
Be sure to subscribe to updates here so you never miss an important development.
Get Real-Time Updates from MJobserver.com